Pierre-Rgis Burgel

List of Publications by Year in Descending Order

139 papers	5,136 citations	38 h-index	68 g-index
176 ext. papers	6,626 ext. citations	6.6 avg, IF	5.31 L-index

#	Paper	IF	Citations
139	Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis.. *Journal of Cystic Fibrosis*, **2022**,	4.1	3
138	Tobramycin safety and efficacy review article.. *Respiratory Medicine*, **2022**, 106778	4.6	0
137	Position paper of the French Society of Respiratory Diseases regarding pharmacological treatment optimization for stable COPD in 2021.. *Respiratory Medicine and Research*, **2022**, 81, 100889	1.4	
136	Clinical practice versus guidelines for the screening of cystic fibrosis-related diabetes: A French survey from the 47 centers.. *Journal of Clinical and Translational Endocrinology*, **2022**, 28, 100298	2.4	
135	Antibiotic resistance in chronic respiratory diseases: from susceptibility testing to the resistome. *European Respiratory Review*, **2022**, 31, 210259	9.8	0
134	CFTR Modulators in People with Cystic Fibrosis: Real-World Evidence in France. *Cells*, **2022**, 11, 1769	7.9	1
133	Major Decrease in Lung Transplantation for Patients with Cystic Fibrosis in France.. *American Journal of Respiratory and Critical Care Medicine*, **2021**,	10.2	6
132	Neuraminidase inhibitors rewire neutrophil function in murine sepsis and in COVID-19 **2021**,		1
131	Using chest CT scan and unsupervised machine learning for predicting and evaluating response to lumacaftor-ivacaftor in people with cystic fibrosis. *European Respiratory Journal*, **2021**,	13.6	1
130	Involvement of CFTR in the pathogenesis of pulmonary arterial hypertension. *European Respiratory Journal*, **2021**, 58,	13.6	5
129	Burden and Characteristics of Severe Chronic Hypoxemia in a Real-World Cohort of Subjects with COPD. *International Journal of COPD*, **2021**, 16, 1275-1284	3	1
128	Real-world assessment of LCI following lumacaftor-ivacaftor initiation in adolescents and adults with cystic fibrosis. *Journal of Cystic Fibrosis*, **2021**,	4.1	2
127	Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020. *Journal of Cystic Fibrosis*, **2021**, 20, 566-577	4.1	10
126	Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function. *Journal of Cystic Fibrosis*, **2021**, 20, 220-227	4.1	13
125	Effective control of lung infection despite tertiary lymphoid structure disorganisation. *European Respiratory Journal*, **2021**, 57,	13.6	2
124	Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: An international observational study. *Journal of Cystic Fibrosis*, **2021**, 20, 25-30	4.1	22
123	"Il faut continuer poser des questions" patient reported outcome measures in cystic fibrosis: An anthropological perspective. *Journal of Cystic Fibrosis*, **2021**, 20, e108-e113	4.1	0

122	Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 204, 64-73	10.2	36
121	Standardisation of Clinical Assessment, Management and Follow-Up of Acute Hospitalised Exacerbation of COPD: A Europe-Wide Consensus. *International Journal of COPD*, **2021**, 16, 321-332	3	5
120	COVID-19 vaccine prioritisation for people with cystic fibrosis. *Journal of Cystic Fibrosis*, **2021**, 20, 715-716	4.1	1
119	Reply to Kuek : Optimism with Caution: Elexacaftor-Tezacaftor-Ivacaftor in Patients with Advanced Pulmonary Disease. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 204, 372-374	10.2	5
118	COVID-19 outcomes in people with cystic fibrosis. *Current Opinion in Pulmonary Medicine*, **2021**, 27, 538-543	3	5
117	Inhaled Dual Phosphodiesterase 3/4 Inhibitors for the Treatment of Patients with COPD: A Short Review. *International Journal of COPD*, **2021**, 16, 2363-2373	3	2
116	Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease. *Respiratory Medicine and Research*, **2021**, 80, 100829	1.4	3
115	Management of early infection with Pseudomonas aeruginosa in adults with bronchiectasis: A survey of French pulmonologists' practices. *Respiratory Medicine and Research*, **2021**, 80, 100859	1.4	
114	Topological data analysis reveals genotype-phenotype relationships in primary ciliary dyskinesia. *European Respiratory Journal*, **2021**, 58,	13.6	12
113	Prednisolone plus itraconazole in acute-stage allergic bronchopulmonary aspergillosis complicating asthma: is the benefit worth the risk?. *European Respiratory Journal*, **2021**,	13.6	
112	Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2015 and GOLD 2019 staging: a pooled analysis of individual patient data. *ERJ Open Research*, **2020**, 6,	3.5	3
111	The global impact of SARS-CoV-2 in 181 people with cystic fibrosis. *Journal of Cystic Fibrosis*, **2020**, 19, 868-871	4.1	34
110	A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis. *Journal of Cystic Fibrosis*, **2020**, 19, 355-358	4.1	73
109	Validation of short- and long-term demographic forecasts using the Canadian Cystic Fibrosis Registry. *European Respiratory Journal*, **2020**, 55,	13.6	1
108	Risk factors for nontuberculous mycobacterial isolation in patients with cystic fibrosis: A meta-analysis. *Pediatric Pulmonology*, **2020**, 55, 2653-2661	3.5	3
107	Prioritising outcomes for evaluating eosinophil-guided corticosteroid therapy among patients with acute COPD exacerbations requiring hospitalisation: a Delphi consensus study. *BMJ Open*, **2020**, 10, e035811	3	1
106	Quantification of Cystic Fibrosis Lung Disease with Radiomics-based CT Scores. *Radiology: Cardiothoracic Imaging*, **2020**, 2, e200022	8.3	2
105	Reduced Intestinal Inflammation With Lumacaftor/Ivacaftor in Adolescents With Cystic Fibrosis. *Journal of Pediatric Gastroenterology and Nutrition*, **2020**, 71, 778-781	2.8	5

104	Antimicrobial resistance in cystic fibrosis: A Delphi approach to defining best practices. *Journal of Cystic Fibrosis*, **2020**, 19, 370-375	4.1	10
103	Arpin is critical for phagocytosis in macrophages and is targeted by human rhinovirus. *EMBO Reports*, **2020**, 21, e47963	6.5	8
102	Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020). *European Respiratory Review*, **2020**, 29,	9.8	50
101	First Wave of COVID-19 in French Patients with Cystic Fibrosis. *Journal of Clinical Medicine*, **2020**, 9,	5.1	14
100	BPCO. *Revue Des Maladies Respiratoires Actualites*, **2020**, 12, A25-A28	0	
99	Lung immunoglobulin A immunity dysregulation in cystic fibrosis. *EBioMedicine*, **2020**, 60, 102974	8.8	11
98	The future of cystic fibrosis care: a global perspective. *Lancet Respiratory Medicine,the*, **2020**, 8, 65-124	35.1	259
97	Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 201, 188-197	10.2	49
96	Impact of COVID-19 on people with cystic fibrosis. *Lancet Respiratory Medicine,the*, **2020**, 8, e35-e36	35.1	74
95	Relationship between gender and survival in a real-life cohort of patients with COPD. *Respiratory Research*, **2019**, 20, 191	7.3	8
94	Cluster and CART analyses identify large subgroups of adults with cystic fibrosis at low risk of 10-year death. *European Respiratory Journal*, **2019**, 53,	13.6	8
93	External Validation and Recalculation of the CODEX Index in COPD Patients. A 3CIAplus Cohort Study. *COPD: Journal of Chronic Obstructive Pulmonary Disease*, **2019**, 16, 8-17	2	4
92	Artificial intelligence outperforms pulmonologists in the interpretation of pulmonary function tests. *European Respiratory Journal*, **2019**, 53,	13.6	45
91	Are there specific clinical characteristics associated with physician treatment choices in COPD?. *Respiratory Research*, **2019**, 20, 189	7.3	3
90	Predictors in routine practice of 6-min walking distance and oxygen desaturation in patients with COPD: impact of comorbidities. *International Journal of COPD*, **2019**, 14, 1399-1410	3	8
89	Randomized controlled trials of pharmacological treatments to prevent COPD exacerbations: applicability to real-life patients. *BMC Pulmonary Medicine*, **2019**, 19, 127	3.5	9
88	Validation of the French 3-year prognostic score using the Canadian Cystic Fibrosis registry. *Journal of Cystic Fibrosis*, **2019**, 18, 396-398	4.1	6
87	Acute and chronic non-pulmonary complications in adults with cystic fibrosis. *Expert Review of Respiratory Medicine*, **2019**, 13, 23-38	3.8	5

86	Reply to Polverino: Deconvoluting Chronic Obstructive Pulmonary Disease: Are B Cells the Frontrunners?. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 199, 1171-1172	10.2	
85	Increased IgA Expression in Lung Lymphoid Follicles in Severe Chronic Obstructive Pulmonary Disease. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 199, 592-602	10.2	24
84	Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 198, 928-940	10.2	38
83	Blood eosinophil counts as a guide for COPD treatment strategies. *Lancet Respiratory Medicine,the*, **2018**, 6, 78-80	35.1	3
82	Large-scale external validation and comparison of prognostic models: an application to chronic obstructive pulmonary disease. *BMC Medicine*, **2018**, 16, 33	11.4	14
81	Peribronchial tertiary lymphoid structures persist after rituximab therapy in patients with cystic fibrosis. *Journal of Clinical Pathology*, **2018**, 71, 752-753	3.9	4
80	A prospective analysis of unplanned patient-initiated contacts in an adult cystic fibrosis centre. *Journal of Cystic Fibrosis*, **2018**, 17, 636-642	4.1	2
79	Exploring the Role of Tertiary Lymphoid Structures Using a Mouse Model of Bacteria-Infected Lungs. *Methods in Molecular Biology*, **2018**, 1845, 223-239	1.4	4
78	An automated computed tomography score for the cystic fibrosis lung. *European Radiology*, **2018**, 28, 5111-5120	8	9
77	Automated computed tomographic scoring of lung disease in adults with primary ciliary dyskinesia. *BMC Pulmonary Medicine*, **2018**, 18, 194	3.5	5
76	An attempt at modeling COPD epidemiological trends in France. *Respiratory Research*, **2018**, 19, 130	7.3	9
75	Clinical characteristics, functional respiratory decline and follow-up in adult patients with primary ciliary dyskinesia. *Thorax*, **2017**, 72, 154-160	7.3	51
74	Bacteria-driven peribronchial lymphoid neogenesis in bronchiectasis and cystic fibrosis. *European Respiratory Journal*, **2017**, 49,	13.6	23
73	The changing epidemiology and demography of cystic fibrosis. *Presse Medicale*, **2017**, 46, e87-e95	2.2	38
72	Real-life initiation of lumacaftor/ivacaftor combination in adults with cystic fibrosis homozygous for the Phe508del CFTR mutation and severe lung disease. *Journal of Cystic Fibrosis*, **2017**, 16, 388-391	4.1	62
71	How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 196, 139-149	10.2	54
70	A simple algorithm for the identification of clinical COPD phenotypes. *European Respiratory Journal* , **2017**, 50,	13.6	35
69	Modelling future trends in cystic fibrosis demography using the French Cystic Fibrosis Registry: update and sensitivity analysis. *European Respiratory Journal*, **2017**, 50,	13.6	9

68	Immediate salbutamol responsiveness does not predict long-term benefits of indacaterol in patients with chronic obstructive pulmonary disease. *BMC Pulmonary Medicine*, **2017**, 17, 25	3.5	6
67	Case series of omalizumab for allergic bronchopulmonary aspergillosis in cystic fibrosis patients. *Pediatric Pulmonology*, **2017**, 52, 190-197	3.5	21
66	Limitations to providing adult cystic fibrosis care in Europe: Results of a care centre survey. *Journal of Cystic Fibrosis*, **2017**, 16, 85-88	4.1	14
65	Relationship between blood eosinophils, clinical characteristics, and mortality in patients with COPD. *International Journal of COPD*, **2017**, 12, 1819-1824	3	54
64	Harnessing Neutrophil Survival Mechanisms during Chronic Infection by : Novel Therapeutic Targets to Dampen Inflammation in Cystic Fibrosis. *Frontiers in Cellular and Infection Microbiology*, **2017**, 7, 243	5.9	9
63	Report of the European Respiratory Society/European Cystic Fibrosis Society task force on the care of adults with cystic fibrosis. *European Respiratory Journal*, **2016**, 47, 420-8	13.6	64
62	DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis. *Clinical Respiratory Journal*, **2016**, 10, 777-783	1.7	8
61	Causes of death in French cystic fibrosis patients: The need for improvement in transplantation referral strategies!. *Journal of Cystic Fibrosis*, **2016**, 15, 204-12	4.1	44
60	Neutrophil-Expressed p21/waf1 Favors Inflammation Resolution in Pseudomonas aeruginosa Infection. *American Journal of Respiratory Cell and Molecular Biology*, **2016**, 54, 740-50	5.7	14
59	in the cystic fibrosis lung: pros and cons of azole therapy. *Infection and Drug Resistance*, **2016**, 9, 229-238	4.2	33
58	Impact of current cough on health-related quality of life in patients with COPD. *International Journal of COPD*, **2016**, 11, 2091-2097	3	28
57	Exacerbations of COPD. *International Journal of COPD*, **2016**, 11 Spec Iss, 21-30	3	58
56	Long-term computed tomographic changes in cystic fibrosis patients treated with ivacaftor. *European Respiratory Journal*, **2016**, 48, 249-52	13.6	15
55	Renin-associated hypertension after bronchial artery embolization in cystic fibrosis. *Journal of Cystic Fibrosis*, **2016**, 15, 213-5	4.1	2
54	CFTR and/or pancreatitis susceptibility genes mutations as risk factors of pancreatitis in cystic fibrosis patients?. *Pancreatology*, **2016**, 16, 515-22	3.8	3
53	Future trends in cystic fibrosis demography in 34 European countries. *European Respiratory Journal*, **2015**, 46, 133-41	13.6	169
52	An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine*, **2015**, 191, e4-e27	10.2	137
51	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. *European Respiratory Journal*, **2015**, 45, 879-905	13.6	107

50	Host-microbe interactions in distal airways: relevance to chronic airway diseases. *European Respiratory Review*, **2015**, 24, 78-91	9.8	23
49	Complications of peripherally inserted central catheters in adults with cystic fibrosis or bronchiectasis. *Journal of Vascular Access*, **2015**, 16, 245-9	1.8	9
48	Modified Medical Research Council scale vs Baseline Dyspnea Index to evaluate dyspnea in chronic obstructive pulmonary disease. *International Journal of COPD*, **2015**, 10, 1663-72	3	51
47	Reduced risk of nontuberculous mycobacteria in cystic fibrosis adults receiving long-term azithromycin. *Journal of Cystic Fibrosis*, **2015**, 14, 594-9	4.1	28
46	Real-life use of long-acting antimuscarinic agents following their approval for COPD treatment. *European Respiratory Journal*, **2015**, 45, 260-2	13.6	4
45	Impact of gender on COPD expression in a real-life cohort. *Respiratory Research*, **2014**, 15, 20	7.3	31
44	Pseudomonas aeruginosa eradicates Staphylococcus aureus by manipulating the host immunity. *Nature Communications*, **2014**, 5, 5105	17.4	82
43	Tiotropium might improve survival in subjects with COPD at high risk of mortality. *Respiratory Research*, **2014**, 15, 64	7.3	8
42	p.Arg75Gln, a CFTR variant involved in the risk of CFTR-related disorders?. *Journal of Human Genetics*, **2014**, 59, 206-10	4.3	8
41	Targeting mucus hypersecretion: new therapeutic opportunities for COPD?. *Drugs*, **2014**, 74, 1073-89	12.1	31
40	Identification of clinical phenotypes using cluster analyses in COPD patients with multiple comorbidities. *BioMed Research International*, **2014**, 2014, 420134	3	45
39	Association of chronic nasal symptoms with dyspnoea and quality-of-life impairment in chronic obstructive pulmonary disease. *Respirology*, **2014**, 19, 346-52	3.6	13
38	Real-life use of inhaled corticosteroids in COPD patients versus the GOLD proposals: a paradigm shift in GOLD 2011?. *European Respiratory Journal*, **2014**, 43, 1201-3	13.6	21
37	Prognostic value of six minute walk test in cystic fibrosis adults. *Respiratory Medicine*, **2013**, 107, 1881-7	4.6	37
36	Association between Staphylococcus aureus alone or combined with Pseudomonas aeruginosa and the clinical condition of patients with cystic fibrosis. *Journal of Cystic Fibrosis*, **2013**, 12, 497-503	4.1	67
35	Impact of comorbidities on COPD-specific health-related quality of life. *Respiratory Medicine*, **2013**, 107, 233-41	4.6	79
34	CFTR dysfunction induces vascular endothelial growth factor synthesis in airway epithelium. *European Respiratory Journal*, **2013**, 42, 1553-62	13.6	15
33	Dysfunctional lung anatomy and small airways degeneration in COPD. *International Journal of COPD*, **2013**, 8, 7-13	3	11

32	Employment and work disability in adults with cystic fibrosis. *Journal of Cystic Fibrosis*, **2012**, 11, 137-43	4.1	22
31	Association between occupational exposure and the clinical characteristics of COPD. *BMC Public Health*, **2012**, 12, 302	4.1	14
30	Everolimus-related organizing pneumonia: a report establishing causality. *Investigational New Drugs*, **2012**, 30, 1244-7	4.3	6
29	Pulmonary acceleration time to optimize the timing of lung transplant in cystic fibrosis. *Pulmonary Circulation*, **2012**, 2, 75-83	2.7	12
28	Targeting cytosolic proliferating cell nuclear antigen in neutrophil-dominated inflammation. *Frontiers in Immunology*, **2012**, 3, 311	8.4	17
27	Bronchial rupture related to endobronchial stenting in relapsing polychondritis. *European Respiratory Review*, **2012**, 21, 367-9	9.8	9
26	Sleep quality and nocturnal hypoxaemia and hypercapnia in children and young adults with cystic fibrosis. *Archives of Disease in Childhood*, **2012**, 97, 960-6	2.2	41
25	Clinical COPD phenotypes identified by cluster analysis: validation with mortality. *European Respiratory Journal*, **2012**, 40, 495-6	13.6	29
24	High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 869-74	5.9	139
23	Two distinct chronic obstructive pulmonary disease (COPD) phenotypes are associated with high risk of mortality. *PLoS ONE*, **2012**, 7, e51048	3.7	86
22	Liver disease in adult patients with cystic fibrosis: a frequent and independent prognostic factor associated with death or lung transplantation. *Journal of Hepatology*, **2011**, 55, 1377-82	13.4	54
21	Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. *Journal of Experimental Medicine*, **2011**, 208, 1635-48	16.6	599
20	Mediastinal tuberculosis in an adult patient with cystic fibrosis. *Journal of Clinical Microbiology*, **2011**, 49, 750-1	9.7	7
19	Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis. *American Journal of Respiratory and Critical Care Medicine*, **2010**, 181, 1078-84	10.2	63
18	beta2-Agonist modulates epithelial gene expression involved in the T- and B-cell chemotaxis and induces airway sensitization in human isolated bronchi. *Pharmacological Research*, **2010**, 61, 121-8	10.2	11
17	Characteristics and consequences of airway colonization by filamentous fungi in 201 adult patients with cystic fibrosis in France. *Medical Mycology*, **2010**, 48 Suppl 1, S32-6	3.9	97
16	Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. *Chest*, **2009**, 135, 975-982	5.3	232
15	Heme oxygenase-1 prevents airway mucus hypersecretion induced by cigarette smoke in rodents and humans. *American Journal of Pathology*, **2008**, 173, 981-92	5.8	36

14	Practice of noninvasive ventilation for cystic fibrosis: a nationwide survey in France. *Respiratory Care*, **2008**, 53, 1482-9	2.1	21
13	A morphometric study of mucins and small airway plugging in cystic fibrosis. *Thorax*, **2007**, 62, 153-61	7.3	94
12	MUC5AC, a gel-forming mucin accumulating in gallstone disease, is overproduced via an epidermal growth factor receptor pathway in the human gallbladder. *American Journal of Pathology*, **2006**, 169, 2031-41	5.8	40
11	Determinants of mortality for adults with cystic fibrosis admitted in Intensive Care Unit: a multicenter study. *Respiratory Research*, **2006**, 7, 14	7.3	31
10	One-year outcome after severe pulmonary exacerbation in adults with cystic fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2005**, 171, 158-64	10.2	90
9	IL-13-induced Clara cell secretory protein expression in airway epithelium: role of EGFR signaling pathway. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2002**, 283, L67-75	5.8	33
8	Mucus and Mucin-Secreting Cells **2002**, 155-163		1
7	Human eosinophils induce mucin production in airway epithelial cells via epidermal growth factor receptor activation. *Journal of Immunology*, **2001**, 167, 5948-54	5.3	119
6	The role of epidermal growth factor in mucus production. *Current Opinion in Pharmacology*, **2001**, 1, 254-8	3.1	68
5	Activation of epidermal growth factor receptors is responsible for mucin synthesis induced by cigarette smoke. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2001**, 280, L165-72	5.8	184
4	IL-13 induces mucin production by stimulating epidermal growth factor receptors and by activating neutrophils. *American Journal of Physiology - Lung Cellular and Molecular Physiology*, **2001**, 280, L134-40	5.8	188
3	Suplatast tosilate inhibits goblet-cell metaplasia of airway epithelium in sensitized mice. *Journal of Allergy and Clinical Immunology*, **2000**, 105, 739-45	11.5	35
2	Relation of epidermal growth factor receptor expression to goblet cell hyperplasia in nasal polyps. *Journal of Allergy and Clinical Immunology*, **2000**, 106, 705-12	11.5	62
1	People living with Moderate-to-Severe COPD Prefer Improvement of Daily Symptoms Over the Improvement of Exacerbations: A Multi-Country Patient Preference Study. *ERJ Open Research*,00686-2021	3.5	0